Improved Speech Intelligibility in Subjects With Stable Sensorineural Hearing Loss Following Intratympanic Dosing of FX-322 in a Phase 1b Study

There are no approved pharmacologic therapies for chronic sensorineural hearing loss (SNHL). The combination of CHIR99021+valproic acid (CV, FX-322) has been shown to regenerate mammalian cochlear hair cells ex vivo. The objectives were to characterize the cochlear pharmacokinetic profile of CV in g...

Descripción completa

Detalles Bibliográficos
Autores principales: McLean, Will J., Hinton, Ashley S., Herby, Jenna T.J., Salt, Alec N., Hartsock, Jared J., Wilson, Sam, Lucchino, David L., Lenarz, Thomas, Warnecke, Athanasia, Prenzler, Nils, Schmitt, Heike, King, Susan, Jackson, Lance E., Rosenbloom, Jeffrey, Atiee, George, Bear, Moraye, Runge, Christina L., Gifford, René H., Rauch, Steven D., Lee, Daniel J., Langer, Robert, Karp, Jeffrey M., Loose, Christopher, LeBel, Carl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Sensorineural Hearing Loss and Tinnitus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279894/
https://www.ncbi.nlm.nih.gov/pubmed/33617194
http://dx.doi.org/10.1097/MAO.0000000000003120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279894/
https://www.ncbi.nlm.nih.gov/pubmed/33617194
http://dx.doi.org/10.1097/MAO.0000000000003120

Ejemplares similares